
Protagonist Therapeutics (PTGX) Stock Forecast & Price Target
Protagonist Therapeutics (PTGX) Analyst Ratings
Bulls say
Protagonist Therapeutics Inc exhibits a promising outlook due to its robust clinical data for icotrokinra, which demonstrates significant dose-dependent improvements in clinical response and remission rates over time, indicating strong potential for effective treatment in inflammatory diseases. The company’s strategic focus on building a diverse pipeline, including rusfertide and continued advancements in its proprietary technology platform, supports sustained growth and innovation within its therapeutic areas. Furthermore, the emphasis on business development and the anticipation of key catalysts in 2025 bolster confidence in the company's future performance and market position.
Bears say
Protagonist Therapeutics Inc faces a challenging outlook due to several significant financial and operational risks inherent in the biopharmaceutical industry. Key concerns include potential unexpected safety issues arising from ongoing clinical trials, the uncertainty of strategic partnerships that may curtail the development of icotrokinra, and escalating regulatory and pricing pressures that could impact market acceptance and profitability. Additionally, the company may encounter financial strain from future cash needs, raising the possibility of dilution for existing shareholders, further complicating its market position.
This aggregate rating is based on analysts' research of Protagonist Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Protagonist Therapeutics (PTGX) Analyst Forecast & Price Prediction
Start investing in Protagonist Therapeutics (PTGX)
Order type
Buy in
Order amount
Est. shares
0 shares